Developing New Cancer Diagnostics and Therapeutics, Giving Novel Insights to Cancer Metastasis

A Novel Approach To Improving Cancer Care

New in-vitro diagnostics are needed to monitor and predict cancer metastasis. This would help stratify patients for optimal treatment and follow-up care. We are developing cancer diagnostics that will give clinicians the power to detect and predict metastasis with high specificity and sensitivity.

New therapeutics for blocking metastatic cancer are important in both early prevention while therapeutic decisions are being made and expanding patient survival. We are working on a new set of blocking molecules that inhibit the ability for the cancer cells to bind and enter the circulation. The diagnostic offers a novel companion diagnostic for this exciting treatment.

With these tests we will redefine the cancer care pathway.

Using non-diluting funds we are entering clinical testing and will be looking for investment later 2022 Q4

Contact us on ryan@MetaGuideX.com




MetaGuideX Management

Dr David Browning

Chair

OBN chair and CEO

CEO Fixed Phage

CEO Oxford Cancer Biomarkers

Amersham International J&J, Philips, NHS.

Dr Ryan Pink

CEO/Co-Founder

Co-inventor

Board member on multiple Oxford healthcare organisations

Biotech consultant for companies like ThermoFisher and Bioline

Clinical researcher €6m Siemens cancer diagnosis tech

Dr Mark Beggs

Advising COO

Experience with Pfizer, Janssen, AstraZeneca and GSK  

CEO, UK Biocentre: quadrupled revenue to >£4m pa

Chief Executive, Stratified Medicine Scotland


Advisory team

Prof Susan Brooks, Co-Founder/inventor – Glycoprotein expert and clinical study experience

Prof Dave Carter, Co-Founder/inventor – Exosome expert, ex-UK Exosome Society President, Research dir. Evox Therapeutics

 Prof Nigel Groome, SABDecades of assay and antibody development. Patented prenatal testing assays totalling a billion tests internationally


Contact us on ryan@metaguidex.com

MetaGuideX Ltd – Company number 12549905